Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Carl Icahn's Firm Expands Grip on Icahn Enterprises LP Holding

2024-06-25
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Carl Icahn's Strategic Acquisition in Icahn Enterprises LP

2024-06-25
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health call volume above normal and directionally bullish

2024-06-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

2024-06-20
LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit ...

Bausch files patent suit against Norwich over generic Xifaxan

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health Defends XIFAXAN® Patent Again

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health files patent infringement lawsuit against Norwich Pharmaceuticals

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tracking John Paulson's Paulson & Company Portfolio - Q1 2024 Update

2024-06-17

With 63% ownership of the shares, Bausch Health Companies Inc. (NYSE:BHC) is heavily dominated by institutional owners

2024-06-16
Key Insights Significantly high institutional ownership implies Bausch Health Companies' stock price is sensitive to...

Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences

2024-06-14
LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare ...